Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Genetic Substudy Shows Fewer Major Cardiovascular Events With Ticagrelor (BRILINTA) Regardless of Relevant Genetic Variability in ACS Patients

August 29, 2010 By Bio-Medicine.Org

WILMINGTON, Del., Aug. 29 /PRNewswire-FirstCall/ — A new
genetic substudy of PLATO (A Study of PLATelet Inhibition
and Patient Outcomes) showed that the effects on a combined
primary endpoint of cardiovascular death, myocardial infarction, or
stroke seen in Acute Coronary Syndromes (ACS) patients who received
the investigational oral antiplatelet treatment, ticagrelor
(BRILINTA™), were maintained, whether or not they had the
genetic variability that has been previously shown to affect a
patient’s response to clopidogrel. The substudy is the
first to look at both efficacy and bleeding endpoints of ACS
patients treated with ticagrelor who carry variations in the
CYP2C19 and ABCB1 genes. The data were presented today at the
European Society of Cardiology (ESC) congress in Stockholm, Sweden
and simultaneously published in The Lancet.  
 

(Logo:
http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

(Logo:
http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO)

CYP2C19

Regardless of the CYP2C19 genotype, the primary outcome occurred
less often with ticagrelor versus clopidogrel (interaction p=0.46).
Ticagrelor event rates were 8.6% per year in carriers  and
8.8% per year in non-carriers of CYP2C19 loss-of-function genotype.
For clopidogrel patients that carried the CYP2C19 loss-of-function
alleles, there was a 11.2% per year event rate, compared to 10.0%
per year for patients without the loss of function allele. Similar
to the overall PLATO study, total major bleeding did not
significantly differ between ticagrelor and clopidogrel regardless
of CYP2C19 genotype.

ABCB1

The genetic substudy also investigated ticagrelor and
clopidogrel treatment outcomes in the three genetic groupings of
the ABCB1 gene group; these were defined as high, intermediate and
low expressions of ABCB1, respectively.  The primary efficacy
event rates for ticagrelor were: 9.5% p

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech